Posters

What is SmartPluse Technology and what are the benefits?

Poster Details

First Author: M. Arbelaez OMAN

Co Author(s):    S. Arba Mosquera                    

Abstract Details

Purpose:

To evaluate the clinical outcomes of SmartSurfACE compared to previous TransPRK in a retrospective setting.

Setting:

Muscat Eye laser Center, Muscat ,Oman

Methods:

The outcomes of SmartSurfACE have been evaluated up to 12M follow-up in 100 eyes and compared to a historic cohort of 100 previous TransPRK treatments. In all cases standard examinations, pre- and postoperative corneal-wavefront analyses (OPTIKON Scout), and ocular-wavefront aberrometries (Ocular Wavefront Analyzer) were performed. CAM software was used to plan Aberration-Free treatments and AMARIS system was used to perform ablations (SCHWIND eye-tech-solutions). Optimised astigmatic corrections were evaluated in terms of efficacy, predictability, stability, safety, and aberrations outcomes.

Results:

SmartSurfACE shows improved UDVA outcomes compared to previous TransPRK from Day 1 (3 lines better) to 1 month (1 line better) postoperatively (p<0.05). At 1 week postoperatively, 42% of the SmartSurfACE treatments reach 20/20 or better, vs. only 16% of the previous TransPRK. Results become equivalent at 3 months (p>0.05) with 100% of the patients having UDVA of 20/25 or better.

Conclusions:

The short term superiority in the SmartSurfACE group could be attributed to the improved residual roughness (enhanced smoothness) of the corneal surface.

Financial Disclosure:

One or more of the authors is employed by a forNONEprofit company with an interest in the subject of the presentation, One or more of the authors travel has been funded, fully or partially, by a competing company